CTL3 Inhibitors represent a class of chemical compounds developed to target and modulate the activity of CTL3, which stands for Choline Transporter-Like Protein 3. CTL3 is a member of the SLC44 transporter family, which plays a critical role in the transport of choline and other organic cations across cell membranes. While the precise functions of CTL3 are still being elucidated, its homology with other choline transporters suggests it may participate in the cellular uptake of choline, a crucial nutrient involved in various biological processes, including membrane synthesis, neurotransmitter production, and lipid metabolism. Inhibitors of CTL3 are designed to interact with this specific protein, potentially influencing its transport activity and, by extension, cellular choline homeostasis.
Structurally, CTL3 Inhibitors are carefully designed to interact with the active sites or binding domains of CTL3, disrupting its normal transport function. This interaction can lead to alterations in cellular choline levels, which, in turn, may impact cell membrane integrity, neurotransmitter release, and lipid metabolism. Research into CTL3 Inhibitors is instrumental in furthering our understanding of choline transport and its role in cellular processes, including its potential implications in various physiological and pathological conditions. Additionally, exploring the modulation of CTL3 may shed light on new avenues for research in fields like neuroscience, where choline and its derivatives have significant roles in neurotransmission, cognition, and brain health.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Valinomycin | 2001-95-8 | sc-200991 | 25 mg | $250.00 | 3 | |
This is a potassium-selective ionophore and can affect the ion balance across membranes, potentially affecting SLC function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a sodium/potassium ionophore which can alter ion gradients and could potentially affect SLC function. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $94.00 $355.00 | 46 | |
This compound uncouples oxidative phosphorylation in mitochondria, which can indirectly affect transporters by altering the cellular energy state. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker that may indirectly affect SLC function due to changes in intracellular calcium. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
Historically used to inhibit organic anion transporters, which are a subset of the SLC superfamily. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
This compound is known to inhibit some SLC transporters, though specificity would need to be validated. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Known to inhibit equilibrative nucleoside transporters, another subset of the SLC family. | ||||||
(±)-Sulfinpyrazone | 57-96-5 | sc-202822 sc-202822A | 1 g 5 g | $42.00 $94.00 | 2 | |
An uricosuric agent that may inhibit some SLC transporters. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
An angiotensin II receptor antagonist that may also affect organic anion transporters. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
A nonsteroidal anti-inflammatory drug (NSAID) that might affect certain transporters. | ||||||